Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$8.61 -3.8%	$8.10	$6.85 ▼ $21.01	$508.12M	-0.04	559,684 shs	264,276 shs
NKTX Nkarta	$1.86 -2.6%	$1.85	$1.31 ▼ $8.23	$131.98M	0.72	1.06 million shs	458,497 shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	26,617 shs	N/A
VALN Valneva	$6.01 -2.3%	$6.46	$3.62 ▼ $8.66	$510.26M	1.81	42,636 shs	12,704 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	0.00%	-5.18%	+18.92%	-2.05%	-60.34%
NKTX Nkarta	0.00%	-2.11%	+8.14%	+12.05%	-70.57%
OPT Opthea	0.00%	0.00%	0.00%	+7.23%	+36.40%
VALN Valneva	0.00%	-2.26%	-2.59%	-11.62%	-28.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	1.6705 of 5 stars	3.5	0.0	2.1	1.7	0.6
NKTX Nkarta	3.6331 of 5 stars	4.6	3.0	3.1	1.7	0.6
OPT Opthea	0.7071 of 5 stars	2.1	0.0	1.5	0.8	0.6
VALN Valneva	2.6393 of 5 stars	3.5	5.0	2.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	248.43% Upside
NKTX Nkarta	3.13	Buy	$14.33	670.61% Upside
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside
VALN Valneva	3.00	Buy	$15.50	157.90% Upside

Current Analyst Ratings Breakdown

Latest NKTX, OPT, CGEM, and VALN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
5/8/2025	VALN Valneva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/16/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
4/15/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/9/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/9/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
3/31/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.61 per share	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.56 per share	N/A
OPT Opthea	$87.67K	5,986.77	N/A	N/A	($0.56) per share	-6.09
VALN Valneva	$186.06M	2.75	N/A	N/A	$2.00 per share	3.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$153.16M	-$2.91	N/A	N/A	N/A	N/A	-26.54%	-25.32%	8/14/2025 (Estimated)
NKTX Nkarta	-$117.50M	-$1.51	N/A	N/A	N/A	N/A	-27.13%	-21.67%	8/12/2025 (Estimated)
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
VALN Valneva	-$109.78M	-$1.19	N/A	N/A	N/A	-4.35%	-3.93%	-1.42%	8/12/2025 (Estimated)

Latest NKTX, OPT, CGEM, and VALN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/7/2025	Q1 2025	VALN Valneva	-$0.40	-$0.13	+$0.27	-$0.13	$41.80 million	$51.79 million
3/26/2025	Q4 2024	NKTX Nkarta	-$0.41	-$0.35	+$0.06	-$0.35	N/A	N/A
3/20/2025	Q4 2024	VALN Valneva	-$0.22	-$0.54	-$0.32	-$0.54	$55.64 million	$56.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	24.46	24.46
NKTX Nkarta	N/A	12.91	12.91
OPT Opthea	N/A	2.94	2.94
VALN Valneva	0.70	2.78	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
NKTX Nkarta	80.54%
OPT Opthea	55.95%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
NKTX Nkarta	8.40%
OPT Opthea	3.20%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.02 million	54.69 million	Optionable
NKTX Nkarta	140	70.96 million	64.43 million	Optionable
OPT Opthea	8	153.91 million	148.98 million	Not Optionable
VALN Valneva	700	85.09 million	69.15 million	Not Optionable

NKTX, OPT, CGEM, and VALN Headlines

Recent News About These Companies

Valneva SE (NASDAQ:VALN) Sees Large Drop in Short Interest

June 14 at 7:59 AM | marketbeat.com

Valneva (NASDAQ:VALN) Stock Price Down 4% - Here's What Happened

June 12 at 1:20 PM | marketbeat.com

Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure

June 10, 2025 | indiaeducationdiary.in

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

June 10, 2025 | reuters.com

Valneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in Children

June 10, 2025 | pharmexec.com

UK restricts use of Valneva chikungunya vaccine for safety review

June 10, 2025 | yahoo.com

UK's MHRA suspends Valneva's chikungunya vaccine for elderly (June 9)

June 10, 2025 | msn.com

Valneva reports data from Phase II chikungunya vaccine trial in children

June 6, 2025 | finance.yahoo.com

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

June 5, 2025 | globenewswire.com

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

June 4, 2025 | globenewswire.com

Valneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?

June 3, 2025 | marketbeat.com

Valneva SE (NASDAQ:VALN) Sees Large Decrease in Short Interest

June 2, 2025 | marketbeat.com

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025 | globenewswire.com

US CDC accepts recommendations for chikungunya vaccines

May 21, 2025 | msn.com

London man among thousands who've rolled up their sleeves to trial Lyme disease vaccine

May 19, 2025 | cbc.ca

US Advises Older Travelers to Avoid Chikungunya Vaccine

May 16, 2025 | infectiousdiseaseadvisor.com

FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

May 15, 2025 | pharmexec.com

FDA, CDC recommend pause in Valneva chikungunya vaccine for older adults

May 14, 2025 | cidrap.umn.edu

U.S. Advises Older Travelers to Avoid Chikungunya Vaccine

May 13, 2025 | usnews.com

FDA warns seniors to avoid this vaccine after deadly complications

May 13, 2025 | msn.com

2VALN : US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For...

May 13, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Industrials Stocks Standing Out for Growth and Analyst Optimism
By Nathan Reiff | June 4, 2025
View 3 Industrials Stocks Standing Out for Growth and Analyst Optimism
Silver's Options Sizzle: Are Traders Betting on a Breakout?
By Jeffrey Neal Johnson | June 5, 2025
View Silver's Options Sizzle: Are Traders Betting on a Breakout?
CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good
By Chris Markoch | May 20, 2025
View CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good
Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?
By Jeffrey Neal Johnson | May 22, 2025
View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?
The Other AI Chipmaker: Why Marvell's Dip Is a Buy
By Jeffrey Neal Johnson | June 12, 2025
View The Other AI Chipmaker: Why Marvell's Dip Is a Buy

NKTX, OPT, CGEM, and VALN Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$8.61 -0.34 (-3.80%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$8.65 +0.04 (+0.52%)

As of 06/13/2025 04:04 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Nkarta NASDAQ:NKTX

$1.86 -0.05 (-2.62%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.88 +0.01 (+0.81%)

As of 06/13/2025 07:58 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Opthea NASDAQ:OPT

$3.41 0.00 (0.00%)

As of 06/13/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Valneva NASDAQ:VALN

$6.01 -0.14 (-2.28%)

As of 06/13/2025 04:00 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time